Nisa Investment Advisors
GLUE icon

Nisa Investment Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Nisa Investment Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
4,911
+160
+3% +$3.02K ﹤0.01% 1464
2026
Q1 		$78.2K Buy
4,751
+1,600
+51% +$30.6K ﹤0.01% 1518
2025
Q4 		$49.4K Buy
3,151
+451
+17% +$6.08K ﹤0.01% 1621
2025
Q3 		$20K Sell
2,700
-48
-2% -$254 ﹤0.01% 1996
2025
Q2 		$12.4K Sell
2,748
-127
-4% -$566 ﹤0.01% 2166
2025
Q1 		$13.3K Buy
2,875
+37
+1% +$227 ﹤0.01% 2022
2024
Q4 		$19.7K Buy
2,838
+79
+3% +$593 ﹤0.01% 1939
2024
Q3 		$14.6K Buy
2,759
+40
+1% +$202 ﹤0.01% 2012
2024
Q2 		$10.2K Buy
2,719
+2,706
+20,815% +$13.8K ﹤0.01% 2148
2024
Q1 		$92 Buy
+13
New +$77 ﹤0.01% 2719
2023
Q4 		– Sell
-1,170
Closed -$5.6K – 2679
2023
Q3 		$5.6K Buy
+1,170
New +$7.53K ﹤0.01% 2271
2023
Q2 		– Sell
-2,190
Closed -$17K – 2828
2023
Q1 		$17K Buy
2,190
+168
+8% +$1.17K ﹤0.01% 2054
2022
Q4 		$15K Buy
2,022
+22
+1% +$183 ﹤0.01% 2120
2022
Q3 		$18K Hold
2,000
– – ﹤0.01% 2076
2022
Q2 		$19K Buy
+2,000
New +$20.1K ﹤0.01% 2057

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nisa Investment Advisors's GLUE Position: Q2 2026 in Review

Nisa Investment Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 3.4% in Q2 2026, buying an estimated $3.02K and bringing the position to 4,911 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

Nisa Investment Advisors first reported a position in GLUE in Q2 2022 and has held it in 15 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Nisa Investment Advisors held 4,911 shares of Monte Rosa Therapeutics worth $119K as of Q2 2026.
  • Nisa Investment Advisors bought 160 Monte Rosa Therapeutics shares in Q2 2026, an estimated $3.02K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1464 holding.
  • Nisa Investment Advisors first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.